Aminostatin derivatives for the treatment of arthrosis

Patent metadata

Field	Value
Publication number	US-9839665-B2
Application number	US-201615041712-A
Country	US
Kind code	B2
Filing date	Feb 11, 2016
Priority date	Feb 8, 2011
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.

First claim

The invention claimed is:

1. A compound of formula I,

in which
I 1 , I 2 , I 3 , I 4 , I 5 , are each CH,
T is phenyl or naphthyl, each of which is unsubstituted or mono-, di- tri- or tetrasubstituted by R, or a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di- or trisubstituted by R, ═S, ═NR′ and/or ═O,
R 1 is ethyl, isopropyl, isobutyl, sec-butyl, tert-butyl or benzyl,
A 1 is 0 to 2 amino acid radicals which are bonded to one another in a peptide-like manner, selected from the group consisting of valine, aminobutyric acid, leucine, isoleucine, tert-leucine or phenylalanine,
A 2 is a single bond or is an amino acid radical selected from the group consisting of cyclopropylglycine, valine, leucine, isoleucine or tert-leucine,
L 1 is a single bond or —CRR′—,
L 2 is a single bond or —NRCR′R—,
X is H, T, linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O, R, T, OR, NRR′, SOR, SO 2 R, SO 2 NRR′, CN, COOR, CONRR′, NRCOR′, NRCONR′R″, NRSO 2 R′ and/or NRCOR′ and in which one, two or three CH 2 groups may each be replaced, independently of one another, by O, S, SO, SO 2 , NR, —OCO—, —NRCONR′—, —NRCO—, —NRSO 2 R′—, —COO—, —CONR—, —C≡C— or —CH═CH— groups and/or, in addition, 1-20 H atoms may each be replaced by F or Cl, or linear or branched cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O, R, T, OR, NRR′, SOR, SO 2 R, SO 2 NRR′, CN, COOR, CONRR′, NRCOR′, NRCONR′R″, NRSO 2 R′ and/or NRCOR′ and in which one, two or three CH 2 groups may each be replaced, independently of one another, by O, S, SO, SO 2 , NR, —OCO—, —NRCONR′—, —NRCO—, —NRSO 2 R′—, —COO—, —CONR—, —C≡C— or —CH═CH— groups and/or, in addition, 1-11 H atoms may each be replaced by F or Cl,
Y is H or a linear or branched alkyl having 1-4 C atoms or a cyclic alkyl having 3-7 C-atoms,
R, R′, independently of one another, are H, linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O, Hal, OH, NH 2 , SO 2 CH 3 , SO 2 NH 2 , CN, CONH 2 , NHCOCH 3 , and/or NHCONH 2 and in which one, two or three CH 2 groups may each be replaced, independently of one another, by O, S, SO, SO 2 , NH, NCH 3 , —OCO—, —NHCONH—, —NHCO—, —NRSO 2 R′—, —COO—, —CONH—, —NCH 3 CO—, —CONCH 3 —, —C≡C— or —CH═CH— groups and/or, in addition, 1-20 H atoms may each be replaced by F or Cl,
m is 0-1,
n is 0-1, and
Hal is F, Cl, Br or I,
with the provisos that:
(a) A 2 is selected from cyclopropylglycine, valine, leucine, isoleucine, or tert-leucine, when L 2 is a single bond and Y is H or a linear or branched alkyl having 1-4 C atoms, and
(b) A 2 is a single bond, when L 2 is —NHCR′R— and Y is H or a cyclic alkyl having 3-7 C-atoms,

or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof, including mixtures thereof in all ratios.

2. A process for the preparation of the compounds according to claim 1 , said process comprising:
a) reacting a compound of formula II, in which I 1 , I 2 , I 3 , I 4 and I 5 have the meanings indicated in claim 1 and Q and Q′ denote mutually orthogonal amino-protecting groups, with a compound of formula III, in which Y, L 2 , n and A 2 have the meanings indicated in claim 1 , with formation of a peptide bond between the carboxyl group of the compound of the formula II and the amino group of the compound of the formula III, to form a compound of formula IVa, and the compound of the formula IVa is converted into a compound of formula IV by cleaving-off of the protecting group Q,

and reacting a compound of formula V, in which X, L 1 , m and A 1 have the meanings indicated in claim 1 , with a compound of formula VI, in which R 1 has the meaning indicated in claim 1 and W denotes an acid-protecting group, with formation of a peptide bond between the carboxyl group of the compound of the formula V and the amino group of the compound of the formula VI, to form a compound of formula VIIa, and the compound of the formula VIIa is converted into a compound of formula VII by cleaving-off of the protecting group W,

and a compound of the formula VII, in which X, L 1 , m, A 1 and R 1 have the meanings indicated in claim 1 , is reacted with a compound of the formula IV, in which I 1 , I 2 , I 3 , I 4 , I 5 , Y, L 2 , n and A 2 have the meanings indicated in claim 1 and Q′ is an amino-protecting group, with formation of a peptide bond between the carboxyl group of the compound of the formula VII and the amino group of the compound of the formula IV, to form a compound of the formula Ia, and the compound of the formula Ia is converted into a compound of the formula I by cleaving-off of the protecting group Q′,

b) converting a base of a compound of the formula I into one of its salts by treatment with an acid, or
c) converting an acid of a compound of the formula into one of its salts by treatment with a base.

3. A method of inhibiting cathepsin D comprising administering to a patient a compound according to claim 1 .

4. A pharmaceutical composition comprising at least one compound according to claim 1 .

5. A pharmaceutical composition according to claim 4 , further comprising at least one excipient and/or adjuvant.

6. A pharmaceutical composition comprising at least one compound according to claim 1 , and at least one further medicament active ingredient.

7. A process for the preparation of a pharmaceutical composition, said process comprising bringing a compound according to claim 1 into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.

8. A kit consisting of separate packs of
an effective amount of a compound according to claim 1 , and
an effective amount of a further medicament active ingredient.

9. A compound according to claim 1 , wherein A 1 is two amino acid radicals which are bonded to one another in a peptide-like manner, wherein said amino acids are selected from the group consisting of valine, aminobutyric acid, leucine, isoleucine, tert-leucine or phenylalanine.

10. A compound according to claim 1 , wherein A 1 is two amino acid radicals which are bonded to one another in a peptide-like manner, and wherein said amino acid radicals are selected from valine and leucine.

11. A compound according to claim 1 , wherein A 1 is 0 to 2 amino acid radicals which are bonded to one another in a peptide-like manner, selected from the group consisting of valine, aminobutyric acid, leucine, isoleucine, tert-leucine or phenylalanine and which are in their S configuration.

12. A compound according to claim 1 , wherein X is T.

13. A compound according to claim 12 , wherein A 1 is 0 amino acid radicals.

14. A compound according to claim 12 , wherein A 2 is a single bond or is an amino acid radical selected from the group consisting of cyclopropylglycine, valine, leucine, isoleucine or tert-leucine, and which are in their S configuration.

15. A compound according to claim 1 , wherein R 1 is ethyl, isopropyl, isobutyl, sec-bu

Assignees

• Merck Patent Gmbh

Inventors

• Klein Markus
• Tsaklakidis Christos
• Guehring Hans
• Leuthner Birgitta

Classifications

• A61K38/08 Primary

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title